Ionis Pharmaceuticals Inc. (IONS) has disclosed a new risk, in the Debt & Financing category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ionis Pharmaceuticals Inc. faces significant risks related to its securities and the global credit markets, particularly if it fails to progress in its programs as anticipated. The company’s share price is vulnerable to fluctuations based on the timing and achievement of various clinical, regulatory, and commercial milestones, which are often based on assumptions outside its control. Failure to meet these milestones or analysts’ forecasts could lead to a decrease in the market price of its common stock, affecting investor confidence. Additionally, the volatility of its securities could complicate liquidation efforts and increase the risk of financial loss for investors.
Overall, Wall Street has a Strong Buy consensus rating on IONS stock based on 17 Buys and 4 Holds.
To learn more about Ionis Pharmaceuticals Inc.’s risk factors, click here.